All News
Filter News
Found 295 articles
-
Attralus Appoints Jake Bauer to Board of DirectorsStrengthens Board with seasoned biopharmaceutical industry executive
7/28/2021
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that Jake Bauer joined the company’s Board of Directors as an independent director.
-
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
7/28/2021
Bristol Myers SquibbBristol Myers SquibbBristol Myers Squibb reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance across the company.
-
Esker Therapeutics Appoints New Team Members and Board Director
7/21/2021
Esker Therapeutics today announced the appointment of several new team members: Kimberly Lindstorm, Ph.D., as vice president, regulatory. Travis Remarchuk, Ph.D., as executive director, CMC. Zhengbin (Bing) Yao, Ph.D., as a member of the board of directors.
-
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Renovacor Announces the Appointment of Marc Semigran, M.D., as Chief Medical OfficerFormer chief medical officer of MyoKardia to lead clinical development at Renovacor
6/2/2021
Renovacor, Inc., an early‑stage biotechnology company developing adeno-associated virus ‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, announced the appointment of Marc Semigran, M.D., as chief medical officer of Renovacor.
-
Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.
-
Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.
-
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
5/6/2021
– On track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) at virtual FSHD International Research Congress in June 2021 – – On track to report data from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease in mid-2021 – – Conference call scheduled for 8:00 a.m. ET today –
-
Bristol Myers Squibb Reports First Quarter Financial Results for 2021
4/29/2021
Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2021, which reflect continued sales growth and advancement of the company’s product pipeline across our four core therapeutic areas.
-
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Chemical Society Spring 2021 Virtual Meeting
4/12/2021
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data related to the optimization of CK-3773274 (CK-274), including the first disclosure of its chemical structure, were presented at the American Chemical Society Spring 2021 Virtual Meeting.
-
Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A
4/1/2021
Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.cardiolrx.com.
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Operating and Financial Results
3/30/2021
Eledon Pharmaceuticals, Inc., (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today reported its fourth quarter and full-year 2020 operating and financial results.
-
In his fifth year as CEO, his take-home was about $20.15 million – an almost $1.7 million base pay plus $13.5 million in stock awards, with another $5 million in incentive plan pay with “other” pay.
-
Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights
3/15/2021
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2020 and highlighted recent corporate progress.
-
BioSpace Movers & Shakers, March 5
3/5/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
3/4/2021
Fulcrum Therapeutics today provided a business update and reported financial results for the fourth quarter and full year of 2020.
-
Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer
3/1/2021
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, announced the appointment of Jessica Stitt as Chief Financial Officer, effective immediately.
-
Cytokinetics Reports Fourth Quarter 2020 Financial Results
2/25/2021
Cytokinetics, Incorporated reported financial results for the fourth quarter and full year 2020. Net loss for the fourth quarter was $43.9 million or $0.62 per share and the net loss for the year 2020 was $127.3 million or $1.97 per share.
-
Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of Certain of Their Senior Notes at “Make Whole” Prices
2/22/2021
Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb”) issued a notice of redemption to The Bank of New York Mellon (successor to The Chase Manhattan Bank (National Association)), as trustee, to redeem (i) all of Bristol Myers Squibb’s 4.000% Notes due 2023
-
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
2/19/2021
Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb”), with its wholly-owned subsidiary Celgene Corporation (“Celgene”) (collectively, the “Offerors”), announced the accepted amounts and pricing terms of their previously announced 20 separate offers to purchase for cash notes issued by the Offerors listed in the tables below for up to an aggregate purchase price of $4.0 billion.